Meeting
2022 ASCO Annual Meeting
Panel Question and Answer
Presenter
Panel Discussion
ASCO
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Education Session
Session Title
Management of HER2-Overexpressing Metastatic Breast Cancer
Track
Breast Cancer
Similar Videos & Slides
Videos & Slides
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
Speaker: Srikala S. Sridhar, FRCPC, MD, MSc
Videos & Slides
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
Speaker: Henry Jacob Conter, MD, MS, MSc
Videos & Slides
2021 ASCO Annual Meeting
First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT).
Speaker: Johann S. De Bono, FRCP, MB, MD, PhD
Videos & Slides
2020 ASCO Virtual Scientific Program
Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.
Speaker: Cora N. Sternberg, FACP, MD